Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
26.08
-1.54 (-5.58%)
At close: Mar 10, 2026, 4:00 PM EDT
26.47
+0.39 (1.50%)
After-hours: Mar 10, 2026, 5:01 PM EDT
Beam Therapeutics Employees
Beam Therapeutics had 511 employees as of December 31, 2025. The number of employees increased by 28 or 5.80% compared to the previous year.
Employees
511
Change
28
Growth
5.80%
Revenue / Employee
$273,470
Profits / Employee
-$156,540
Market Cap
2.59B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 511 | 28 | 5.80% |
| Sep 30, 2025 | 510 | 38 | 8.05% |
| Jun 30, 2025 | 509 | 48 | 10.41% |
| Mar 31, 2025 | 393 | 47 | 13.58% |
| Dec 31, 2024 | 483 | 47 | 10.78% |
| Sep 30, 2024 | 472 | 33 | 7.52% |
| Jun 30, 2024 | 461 | -71 | -13.35% |
| Mar 31, 2024 | 346 | -177 | -33.84% |
| Dec 31, 2023 | 436 | -71 | -14.00% |
| Sep 30, 2023 | 439 | -68 | -13.41% |
| Jun 30, 2023 | 532 | 56 | 11.76% |
| Mar 31, 2023 | 523 | 129 | 32.74% |
| Dec 31, 2022 | 507 | 166 | 48.68% |
| Sep 30, 2022 | 507 | 201 | 65.69% |
| Jun 30, 2022 | 476 | 210 | 78.95% |
| Mar 31, 2022 | 394 | 178 | 82.41% |
| Dec 31, 2021 | 341 | 160 | 88.40% |
| Sep 30, 2021 | 306 | 140 | 84.34% |
| Jun 30, 2021 | 266 | 115 | 76.16% |
| Mar 31, 2021 | 216 | 98 | 83.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Apellis Pharmaceuticals | 739 |
| Arcus Biosciences | 601 |
| Travere Therapeutics | 497 |
| Arcutis Biotherapeutics | 354 |
| Wave Life Sciences | 317 |
| Dyne Therapeutics | 258 |
| Vera Therapeutics | 224 |
| Catalyst Pharmaceuticals | 182 |
BEAM News
- 11 days ago - Beam Therapeutics: Great Potential, But Patience Is Needed - Seeking Alpha
- 13 days ago - Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - What's Going On With Beam Therapeutics Stock? - Benzinga
- 14 days ago - Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - GlobeNewsWire
- 14 days ago - Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street - GlobeNewsWire
- 15 days ago - Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Beam Therapeutics: Pivoting From Platform To Execution Stage - Seeking Alpha